🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hamburg
Clinical trial register · Germany

Clinical Trials in Hamburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf74 AstraZeneca56 Janssen Research & Development, LLC33 Eli Lilly and Company30 Novartis Pharmaceuticals26
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Hamburg

889 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Berlin, Cologne, Hamburg, Hanover, Heidelberg, Leipzig, Mainz, Würzburg
2026-02-16
Recruiting
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
NCT07298044Transthyretin Amyloid Cardiomyopathy
DrugAcoramidis
Bayer
Phase 4
50
Ulm, Darmstadt, Greifswald, Bonn, Berlin, Hamburg
2026-02-13
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dovato·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
Berlin, Cologne, Frankfurt, Hamburg, München
2026-02-11
Recruiting
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
NCT07197944Short Bowel Syndrome
DrugGlepaglutide
Zealand Pharma
Phase 3
90
Rostock, Leipzig, Aachen, Berlin, Bonn, Hamburg
2026-02-11
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Bochum, Bünde, Duisburg, Hamburg, Karlsruhe, Leipzig, München, Offenbach
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Cologne, Dresden, Duisburg, Essen, Hamburg, Leipzig, Lingen, Mainz
2026-02-06
Recruiting
BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
NCT07564219Multiple Myeloma (MM), CAR T Cells, Bispecific Antibodies
Universitätsklinikum Hamburg-Eppendorf
Not applicable
45
Hamburg
2026-01-30
Recruiting
Targeting Real World Usage In Stroke Treatment
NCT07474935Saccular and Fusiform Aneurysms, Pseudoaneurysm, Vascular Dissection, Perforation
Phenox GmbH
Observational
5,000
Erfurt, Hamburg, Heidelberg, München, Nuremberg
2026-01-29
Recruiting
Oscillometric Versus Intraarterial Blood Pressure Monitoring During Robot-Assisted Prostatectomy
NCT07349186Intraoperative Hypotension
University of Hamburg-Eppendorf
Not applicable
210
Hamburg
2026-01-29
Recruiting
Treatment of Complex Post-traumatic Stress Disorder Among Displaced People in Switzerland and Germany
NCT07015567Complex Post-Traumatic Stress Disorder
Eva Heim
Not applicable
288
Hamburg
2026-01-21
Recruiting
Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery
NCT07129551Prostate Cancer (Adenocarcinoma)
Martini-Klinik am UKE GmbH
Not applicable
102
Hamburg
2026-01-21
Recruiting
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
DrugsKeytruda·Pembrolizumab
Eikon Therapeutics
Phase 1/2
160
Hamburg
2026-01-20
Not yet open
Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension
NCT07294794Hypertension
University of Birmingham
Not applicable
400
Hamburg
2026-01-19
Recruiting
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
NCT07176312Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer, PDL-1
DrugsMFOLFOX·Zanidatamab·Pembrolizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
80
Berlin, Bielefeld, Dresden, Essen, Frankfurt, Göttingen, Hamburg, Herne
2026-01-16
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Bad Bentheim, Berlin, Cottbus, Hamburg, Heidelberg, Mainz, Remscheid, Witten
2026-01-15
Recruiting
Hands-on Emotion Awareness and Regulation Group Training for Autistic Adolescents (HEART)
NCT07009522Study Group
Universitätsklinikum Hamburg-Eppendorf
Phase EARLY_PHASE1
21
Hamburg
2026-01-15
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
2026-01-09
Recruiting
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
NCT07223697Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
120
Bad Bentheim, Hamburg
2026-01-08
Recruiting
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
NCT07284433Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Phase 1/2
178
Ulm, Erlangen, Munich, Marburg, Essen, Dresden, Berlin, Hamburg
2026-01-06
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
NCT07219043Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 2
81
Berlin, Dresden, Hamburg
2026-01-05
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Berlin, Bonn, Detmold, Dresden, Düsseldorf, Essen, Frankfurt am Main, Hamburg
2025-12-29
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
Freiburg im Breisgau, Hamburg, Stuttgart
2025-12-19
Active, closed
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686Obesity, Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
Berlin, Essen, Hamburg, Hanover, Karlsruhe, Oldenburg
2025-12-19
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Docetaxel
Janssen Research & Development, LLC
Phase 3
800
Dresden, Duisburg, Essen, Hamburg, München, Nürtingen
2025-12-19
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Munich, Leipzig, Bad Homburg, Berlin, Cologne, Dresden, Essen, Hamburg
2025-12-19
Recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity, Overweight
DrugRibupatide
Kailera
Phase 3
2,340
Tübingen, Falkensee, Cologne, Essen, Dresden, Leipzig, Oldenburg in Holstein, Hamburg
2025-12-18
Recruiting
WATCHMAN FLX Pro European Registry
NCT07262255Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure
Boston Scientific Corporation
Observational
1,000
Bad Oeynhausen, Berlin, Erfurt, Hamburg, Lübeck
2025-12-17
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736Asthma
Chiesi Farmaceutici S.p.A.
Phase 2
780
Ahrensburg, Berlin, Cottbus, Delitzsch, Düsseldorf, Hamburg, Ibbenbueren, Leipzig
2025-12-17
Recruiting
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
NCT06722183Colorectal Cancer
DrugTislelizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
33
Amberg, Berlin, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Mainz, München
2025-12-16
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Bad Doberan, Berlin, Hamburg, Sendenhorst
2025-12-15
Recruiting
Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma
NCT07270991Metastatic Oesogastric Adenocarcinoma
DrugsTrifluridine/Tipiracil·Fruquintinib
Federation Francophone de Cancerologie Digestive
Phase 3
324
Chemnitz, Essen, Frankfurt, Hamburg, Jena, Leipzig, München, Rostock
2025-12-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Berlin, Bünde, Essen, Hamburg, Münster, Oldenburg
2025-12-15
Recruiting
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
NCT07059299Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma
DrugTislelizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1
18
Frankfurt, Hamburg, Leipzig, München
2025-12-12
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
DrugsPF-08634404·Avastin·Bevacizumab
Pfizer
Phase 3
800
Frankfurt am Main, Leipzig, Berlin, Dresden, Hamburg, München
2025-12-11
Recruiting
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF
NCT07181590Paroxysmal AF, Atrial Arrhythmia, Atrial Fibrillation, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
300
Bad Oeynhausen, Cologne, Hamburg, München
2025-12-11
Active, closed
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT07228403Short Bowel Syndrome (SBS)
DrugGlepaglutide
Zealand Pharma
Phase 3
28
Frankfurt am Main, Rostock, Bonn, Berlin, Hamburg
2025-12-11
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Heidelberg, Würzburg, Marburg, Cologne, Jena, Hamburg
2025-12-10
Recruiting
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis
UCB Biopharma SRL
Phase 1
392
Berlin, Hamburg, Ratingen, Wetzlar
2025-12-10
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Cologne, Hamburg, Heidelberg, Tübingen
2025-12-09
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Aachen, Berlin, Bonn, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg
2025-12-04
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Aschaffenburg, Bielefeld, Bochum, Chemnitz, Cologne, Düsseldorf, Essen, Hamburg
2025-12-03
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Cologne, Essen, Goch, Hamburg, Oldenburg, Stuhr
2025-12-01
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Berlin, Bonn, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Jena
2025-11-28
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
DrugRina-S
Genmab
Phase 3
660
Hamburg, Lemgo, Berlin
2025-11-28
Recruiting
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
NCT07281833Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
DrugCapivasertib
Women's Cancer Study Group GmbH
Phase 3
250
Cologne, Essen, Mönchengladbach, Münster, Frankfurt, Hamburg, Hildesheim, München
2025-11-27
Recruiting
A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)
NCT07012629Covert Brain Infarction
DrugsRosuvastatin·Atorvastatin·Clopidogrel·Aspirin
Aarhus University Hospital
Phase 3
1,652
Hamburg
2025-11-26
Recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
Berlin, Essen, Hamburg, Hanover, Karlsruhe, Oldenburg
2025-11-25
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
Hamburg, Marburg
2025-11-19
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin
Summit Therapeutics
Phase 3
600
Berlin, Bonn, Hamburg
2025-11-18
Recruiting
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
NCT07260175Cholangiocarcinoma, IDH Mutation
DrugIvosidenib
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
40
Aachen, Bonn, Essen, Frankfurt, Giessen, Göttingen, Hamburg, Jena
2025-11-18
Recruiting
Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma
NCT07564570Metastatic Melanoma
Universitätsklinikum Hamburg-Eppendorf
Not applicable
40
Hamburg
2025-11-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
250
Berlin, Erlangen, Hamburg, Kiel, Leipzig, Mainz, München, Münster
2025-11-13
Active, closed
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577Atopic Dermatitis
DrugGIA632
Novartis Pharmaceuticals
Phase 2
34
Berlin, Hamburg, Mainz
2025-11-10
Recruiting
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
NCT05293080Acute Ischemic Stroke, Atrial Fibrillation
Universitätsklinikum Hamburg-Eppendorf
Phase 3
1,746
Hamburg
2025-11-06
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsProcarbazine·Breyanzi·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Freiburg im Breisgau, Ulm, Cologne, Essen, Chemnitz, Berlin, Göttingen, Hamburg
2025-11-06
Active, closed
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642Obesity, Overweight
DrugCagrilintide
Novo Nordisk A/S
Phase 3
300
Essen, Hamburg, Oldenburg in Holstein
2025-11-05
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of the VCFix Spinal System for Treatment of Vertebral Compression Fractures
NCT07301749Vertebral Compression Fracture
Amber Implants B.V.
Not applicable
148
Hamburg, Mechernich
2025-11-04
Not yet open
Evaluating Healthcare Professionals' Satisfaction and Stress Mitigation Using Virtual Reality Intervention in Surgical Ward
NCT07155681Stress, Stress (Psychology)
Amsterdam UMC, location VUmc
Not applicable
75
Hamburg
2025-11-01
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
DrugGSK3862995B
GlaxoSmithKline
Phase 2
363
Bendorf, Berlin, Frankfurt, Geesthacht, Hamburg, München
2025-10-30
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin
BioNTech SE
Phase 3
558
Augsburg, Bremen, Frankfurt, Freiburg im Breisgau, Gera, Hamburg, Koblenz, Mannheim
2025-10-30
Recruiting
The HIgh-fidelity Hydraulic couPling Upper-arm Cuff Assessment of Limits, Safety, and Effectiveness (HIPULSE) Trial (Cardiac Output Study)
NCT06895603ICU, Pulmonary Artery Catheter (PAC), Swan-Ganz Catheter
Philips Clinical & Medical Affairs Global
Observational
75
Hamburg
2025-10-28
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Bad Homburg, Berlin, Hamburg
2025-10-28
Recruiting
Existential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU)
NCT07312760Advanced Cancer, Various, NOS
Universitätsklinikum Hamburg-Eppendorf
Not applicable
160
Düsseldorf, Hamburg, Würzburg
2025-10-24
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg
2025-10-24
Recruiting
Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
NCT07267949Atrial Fibrillation (AF)
Acesion Pharma
Phase 2
200
Coburg, Frankfurt, Hamburg
2025-10-22
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Bendorf, Berlin, Essen, Frankfurt, Hamburg, Leipzig, Mainz, Offenbach
2025-10-22
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-15
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
DrugsTulisokibart·Methotrexate
Merck Sharp & Dohme LLC
Phase 2
185
München, Cottbus, Ratingen, Berlin, Hamburg
2025-10-08
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488Multiple Myeloma
DrugsMezigdomide·Elranatamab·Dexamethasone
Celgene
Phase 1/2
62
Dresden, Hamburg, Heidelberg
2025-10-07
Recruiting
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106Breast Cancer
DrugsRGT-419B·Giredestrant·Abemaciclib
Genentech, Inc.
Phase 1/2
285
Tübingen, Essen, Hamburg
2025-10-07
Recruiting
COMS for Chronic Ulcers Treatment
NCT06528873Venous Leg Ulcer, Wound Heal, Magnetic Field Exposure
Sebastian Probst
Phase 4
122
Essen, Hamburg
2025-10-01
Not yet open
"A Privacy-protecting Environment for Child Transplants Health Related and Genomic Data Integration in the European Reference Network"
NCT07194057Transplant Complication, Kidney Transplant, Liver Transplant
Instituto de Investigación Hospital Universitario La Paz
Observational
200
Hamburg
2025-09-30
Recruiting
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
NCT06855134Rare Cancer
German Cancer Research Center
Observational
946
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2025-09-29
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Heidelberg, Nürtingen, Ulm, Mettmann, Lübeck, Berlin, Düsseldorf, Hamburg
2025-09-28
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Munich, Cottbus, Herne, Ratingen, Berlin, Hamburg
2025-09-26
Recruiting
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
NCT07290257Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
DrugMaralixibat
Mirum Pharmaceuticals, Inc.
Phase 4
230
Berlin, Essen, Hamburg
2025-09-25
Recruiting
International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study
NCT07164378Age - Related Macular Degeneration (AMD)
VisionCare, Inc.
Not applicable
44
Hamburg, Sulzbach, Trier, Würzburg
2025-09-23
Recruiting
AID-FOG: Artificial Intelligence-Driven Freezing of Gait Detection in the Home
NCT07580612Parkinson Disease, Idiopathic, Freezing of Gait, Validation, Wearable Sensors
KU Leuven
Observational
126
Hamburg
2025-09-22
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb
Phase 3
3,040
Freiburg im Breisgau, Langenau, Mahlow, Hamburg, Bad Bentheim, Münster, Mainz, Quedlinburg
2025-09-22
Active, closed
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,101
Aachen, Bad Homburg, Bayreuth, Bochum, Bremen, Erbach/Odenwald, Freiburg im Breisgau, Hamburg
2025-09-17
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Ahrensburg, Augsburg, Berlin, Darmstadt, Frankfurt, Frankfurt am Main, Hamburg, Leipzig
2025-09-16
Recruiting
Hamburg Acute Renal Injury Study (HARIS)
NCT07338669Acute Kidney Injury, Acute Kidney Injury (AKI)
Universitätsklinikum Hamburg-Eppendorf
Observational
1,000
Hamburg
2025-09-16
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Bochum, Dresden, Hamburg, Hanover, Karlsruhe, Leipzig, München, Offenbach
2025-09-15
Recruiting
European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™
NCT07668687Dissection of Thoracic Aorta, Dissection of Thoracic Descending Aorta, Aneurysm of Aorta, Thoracic, Penetrating Aortic Ulcers (PAUs)
Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd
Observational
100
Hamburg, Münster
2025-09-12
Recruiting
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT07039110Plaque Psoriasis
AbbVie
Observational
700
Friedrichshafen, Kulmbach, Munich, Potsdam, Dortmund, Mainz, Mölln, Hamburg
2025-09-09
Recruiting
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
NCT07115745Refractory Autoimmune Diseases
DrugsTocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
125
Düsseldorf, Kiel, Berlin, Dresden, Hamburg
2025-09-04
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
Braunschweig, Duisburg, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Heidelberg, München
2025-09-02
Not yet open
5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab
NCT07124884Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2
300
Bochum, Frankfurt, Göttingen, Hamburg
2025-08-31
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugEfgartigimod PH20
argenx
Observational
200
Berlin, Bochum, Cologne, Düsseldorf, Frankfurt, Giessen, Göttingen, Hamburg
2025-08-11
Recruiting
External Validation of the MASCAN Score for the Classification of Difficult Mask Ventilation
NCT07114549Airway Management, General Anesthesia, Mask Ventilation
Universitätsklinikum Hamburg-Eppendorf
Observational
926
Hamburg
2025-08-08
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Ulm, Erlangen, Berlin, Hamburg
2025-08-05
Recruiting
Delirium and Cognitive Impairment Development in Hospitalized Older Adults Under Isolation Conditions
NCT07114458Delirium, Dementia, Cognitive Impairment
Universitätsklinikum Hamburg-Eppendorf
Observational
404
Hamburg
2025-08-05
Recruiting
Imaging and Serological Biomarkers of Autonomic Dysfunction After Ischemic Stroke
NCT06740942Acute Ischemic Stroke, Transient Ischemic Attack
Universitätsklinikum Hamburg-Eppendorf
Observational
100
Hamburg
2025-08-04
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Amberg, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-08-01
Recruiting
Analysis of Safety and Tissue Interaction of Injectable Biosmulators
NCT06993558This Study Aims to Evaluate the Safety Profile and Tissue Changes After Biostimulatory Treatments to the Face in Healthy Volunteers
Universitätsklinikum Hamburg-Eppendorf
Not applicable
90
Hamburg
2025-07-31
Active, closed
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation
NCT06808217Atrial Fibrillation, Pulsed Field Ablation, FARAPULSE
Boston Scientific Corporation
Observational
550
Berlin, Frankfurt, Hamburg
2025-07-30
Recruiting
Thoracoabdominal Artery Stent Graft System Exploratory Study
NCT06710938Thoracoabdominal Aortic Aneurysms
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
11
Hamburg
2025-07-24
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
Heidelberg, Munich, Würzburg, Hamburg
2025-07-23
Rows per page Showing 101–200 of 889
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/hamburg?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 889 of those studies with a site in Hamburg.

How many clinical trials are recruiting in Hamburg?

452 of the 889 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 34 have not yet opened recruitment, 387 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.